Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2014 | Update on the clinical management of diffuse large B-cell lymphoma

Christian Gisselbrecht, Michael Pfreundschuh and Rich Fisher • 5 Sep 2014
iwNHL 2014
Non-Hodgkin Lymphoma

At the iwNHL 2014, Prof Michael Pfreundschuh (Saarland University Medical School, Homburg, Germany), Dr Rich Fisher (Fox Chase Cancer Center, Pennsylvania, USA) and Prof Christian Gisselbrecht (Hôpital Saint-Louis, Paris, France) discuss the biology and management of diffuse large B-cell lymphoma (DLBCL). Dr Fisher describes the difficulties in defining and managing patients who are not cured by standard therapy. The classification of DLBCLs is an important consideration for research studies and clinical management. ‘Double-hit’ lymphomas have poor prognosis and management options are discussed. Prof Gisselbrecht describes important recent advances in treatment options for different DLBCL subtypes. Future research directions and their impact on patients are also examined.

More from Christian Gisselbrecht

2:25
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
Christian Gisselbrecht • 25 Apr 2023
2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
1:15
The current status of autologous transplantation in PTCL
Christian Gisselbrecht • 25 Apr 2023
2:11
LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT
Christian Gisselbrecht • 31 Aug 2020

More from Michael Pfreundschuh

8:13
Describing clonal evolution in lymphoma
Michael Pfreundschuh et al. • 8 Sep 2017
23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015
9:18
iwNHL 2015 roundtable: Using B-cell biology to inform therapy
Kieron Dunleavy et al. • 3 Oct 2015
26:58
iwNHL 2016: Highlights from Day 2
Anas Younes et al. • 25 Sep 2016

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals